The board needs to see where a coherent product story stops being exact.

I would help an insurance board examine the relationship between the product management account and the proposition a person is being invited to understand. A base benefit can be described beside an option while the package name makes both sound included. An aggregate limit can be prominent while its per-item condition loses significance in the reader’s interpretation. The explanatory material may exist in the material without preserving the relationship that matters to the decision. Collective oversight needs an account of that distinction, not simply reassurance that the document contains the relevant words.

My perspective is grounded in a defined product remit at the fictional Neravelle Assurance. I lead 172 colleagues through seven direct reports with CNY 94 million delegated 2026 function expense. Underwriting, actuarial pricing, claims, legal interpretation, finance and regulatory approvals remain separately accountable. Company gross written premium of CNY 26 billion in 2025 is institutional context. I would bring experience of connecting product explanations with those responsibilities while recognising that a product leader’s view cannot substitute for the specialised judgements required around an insurer’s business.

The small-shop prototype would support a concrete question about the opening proposition. Seventy-eight of 120 owners assumed an income benefit was included in a physical-damage base. We separated the base and optional descriptions, supported CNY 12 million development and retained nineteen unresolved interpretations in a different 100-reader exercise. A board should be able to see why management delayed the proposed launch and what further work it intended. The improved account was not actual sales, a universal comprehension finding or an approval of live coverage.

The renewal comparison would raise a different oversight question. Twenty-four proposed wordings changed benefit limits and twelve changed presentation only. I rejected one administrative-update label across all thirty-six. The funded programme made the effect of the proposed revisions more distinguishable, while their actual approval and any customer response remained separate. A board could ask whether a convenient internal label is obscuring what the proposition means to the person considering it. That inquiry does not require directors to run the wording programme themselves.

My own waiting-period summary belongs beside those examples. I approved immediate-protection language in an invented scenario with a thirty-day illness waiting period. Twenty-two of sixty readers interpreted illness protection from day one. Lanqiu Zhen challenged the headline, and I withdrew it rather than rely on the qualification elsewhere. The later exercise still had nine unresolved interpretations. I would expect a governance account to retain both my responsibility for the first statement and the limit of its correction, instead of describing the result as complete understanding or shifting the mistake to the reader.

I have presented to Neravelle’s board as CPO since July 2019, with no statutory seat in this fictional career. A first appointment would require preparation for collective responsibilities, the institution’s financial and risk account and its applicable setting. I would work through the chair and established management channels. Committee participation would depend on a clear remit and an assessment of preparation; no chair claim follows from executive exposure alone. Product familiarity should help make a question precise without turning a non-executive into a second product sponsor.

Employment, distribution, supplier, financial and personal connections would need disclosure before any assessment of independence. Twenty-six annual days would remain conditional on employer agreement, induction and the demands of the actual role. Policyholder identities, claim histories and restricted wordings would not travel into a public account or another institution without appropriate authority. These invented cases make a pattern of judgement available for scrutiny. A real nomination record would need verified experience and authorised evidence, with the board retaining its own responsibility to assess suitability, capacity and the contribution required.